Senzime is a Swedish medical technology company that develops and markets CE-marked and FDA-approved medical technology systems, powered by unique algorithms and disposable sensors that assess the patient’s muscle function before, during and after surgery with anaesthesia. The company’s goal is to contribute to improved clinical precision and simplified care management.

Senzime’s system, called TetraGraph®, digitally and continuously measures the degree of neuromuscular blockade in order to prevent complications. Fewer complications lead to less suffering for patients but also contribute to shorter hospital stays and reduced healthcare costs. Senzime’s vision is for TetraGraph® to be used in every surgery where muscle relaxants are used, for a safe recovery for all patients.

Senzime’s development portfolio also includes innovative, patient-oriented solutions that enable automated and continuous measurement of biological substances such as glucose and lactate in blood and tissue fluids – CliniSenz® Analyzer and OnZurf® Probe.

Senzime operates in a growing global market that is currently valued at over SEK 15 billion annually in Europe and the US alone. Today, Senzime has sales in 29 countries, of which the most important markets are the USA, Germany, France, Italy, the UK, Spain, Switzerland, South Korea and Japan. The company’s stock is traded on the Nasdaq First North Growth Market (ticker SEZI) and plans to move to Nasdaq Stockholm’s main list in 2021.